SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Jetstar to Charge for Overhead Cabin Bags From February 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
Apple Restores Telegram to App Store After Content Policy Violation 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
SAINT LAURENT, Quebec, March 23, 2018 -- IntelGenx Technologies Corp. (TSX VENTURE:IGX) (OTCQX:IGXT) today announced that it will release its fourth quarter and full year 2017 financial results after market close on March 29, 2018.
An accompanying conference call will be hosted by Dr. Horst G. Zerbe, President and Chief Executive Officer, and Mr. Andre Godin, Executive Vice-President and Chief Financial Officer, to discuss the results and provide a business update. Details of the conference call and webcast are below:
Date: Thursday, March 29, 2018
Time: 4:30 p.m. EDT
Conference dial-in: (833) 211-3233
International dial-in: (647) 689-3955
Conference ID: 6786519
Webcast Registration: Click here
Following the live call, a replay will be available on the Company's website, www.intelgenx.com, under "Investor Relations."
About IntelGenx:
Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.
IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to its clients. More information about the company can be found at www.intelgenx.com.
Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Source: IntelGenx Technologies Corp.
For more information, please contact: Stephen Kilmer Investor Relations (514) 331-7440 ext 232 [email protected] Or Andre Godin, CPA, CA Executive Vice-President and CFO IntelGenx Corp. (514) 331-7440 ext 203 [email protected]
